Moffitt Cancer Center has initiated a major effort to increase the number of investigator-initiated early phase clinical studies. For FY2005, investigators at Moffitt Cancer Center enrolled 490 patients on pilot, phase I or I studies. The Clinical Investigations Program has significantly expanded the phase I effort since the previous submission in 2000. The percentage of subjects enrolled onto Investigator-initiated trials has almost doubled (23% to 44%) over the course of the previous grant period. The proportion of accruals to phase I or I/I I studies remains above 40% of all accruals. The support of innovative phase I and feasibility studies is a clear institutional priority for the coming years of the grant cycle. The scope of this important activity will include outpatient based studies as well as studies conducted for inpatients. Phase I and feasibility studies will take place in both arenas, staffed by research nurses who will supplement the data management core. The maturation of interactions between basic scientists and clinicians, the interprogrammatic working groups, and the establishment of the clinical research unit and translational laboratory support the need for increased numbers of experienced research nursing staff. The institution continues to support the growth of the Phase I Program as demonstrated by the expansion of the Clinical Research Unit in 2001. The current outpatient CRU outpatient area consists of seven treatment rooms (seven beds), 3 infusion area (9 infusion chairs) and three offices, which house five research nurses, two study coordinators, two physician assistants and the Manager of the CRU. Further expansion of this area will be complete in 2007 and will provide additional treatment areas that will expand capacity by at least 60%.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-10
Application #
7579068
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-02-01
Budget End
2009-01-31
Support Year
10
Fiscal Year
2008
Total Cost
$142,512
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Gonzalez, Brian D; Small, Brent J; Cases, Mallory G et al. (2018) Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer 124:499-506
Puri, Sonam; Hyland, Kelly A; Weiss, Kristine Crowe et al. (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26:2911-2918
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Kasting, Monica L; Christy, Shannon M; Sutton, Steven K et al. (2018) Florida physicians' reported use of AFIX-based strategies for human papillomavirus vaccination. Prev Med 116:143-149
Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88
Park, Jae H; Rivière, Isabelle; Gonen, Mithat et al. (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 378:449-459
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2018) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol 26:552-556

Showing the most recent 10 out of 1254 publications